• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Port Info

• Ships in Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• The Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Ahmedabad , June 10

GERMAN Remedies, part of the Zydus Group, has announced the launch of Fludarabine, a drug used for the treatment of chronic lymphocytic leukaemia (blood cancer).

The orally-administered drug, being marketed as Fludara Oral, has been introduced for the first time in the country and is a product of Berlex Inc, a US affiliate of Schering AG Germany, a Zydus Cadila executive told Business Line here.

Chronic lymphocytic leukaemia is a cancer of the lymphocytes. It is a serious, progressive disease, which has no cure and occurs mostly in people over 50 years of age.

"Fludarabine has emerged as one of the leading drugs for treatment - whether as a stand-alone therapy or in combination with other drugs. It helps control the disease by shortening the life span of existing leukaemia cells and interferes with the making of new DNA, thus preventing cancerous cells from growing. With this treatment, the remission can last for several years, thereby increasing the span of survival," the company executive said.

Till very recently, the only way to administer the drug was through an intra-venous injection, which is time consuming.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
World Park sets up hotel at Rameswaram

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line